#ESCCongress: EMPEROR-Reduced Trial Meets Primary Endpoint
- Cardio
- 29/08/2020
In a Hot Line session today at ESC Congress 2020, findings from the EMPEROR-Reduced trial showed that empagiflozin reduces the risk of cardiovascular death or hospitalisation for heart failure in...
READ MORE